Until recently, advancements in the treatment of patients with adult soft tissue sarcomas
have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better …

Importance Immune checkpoint inhibitors have shown promising results in several cancers
and are now put to the test in sarcomas. This brief summary presents data regarding the …

Introduction: Soft tissue sarcomas (STS) are a rare and difficult to treat malignancy. Efforts to
utilize targeted therapy have been ongoing for the last decade and have resulted in the …

At the recent 2022 American Society of Clinical Oncology (ASCO) annual meeting, the latest
progress was presented in clinical trials of various therapeutic modalities for adult soft tissue …

A wide variety of cytogenetic abnormalities and molecular pathways have been implicated in
the pathogenesis of sarcoma, and significant progress has been made in the past decade …

The individual rarity of the many subtypes of soft tissue sarcomas has historically mandated
an empiric approach to systemic therapy. Doxorubicin, first reported to have activity in …

Introduction: Soft tissue sarcomas (STS) encompass a group of rare and heterogeneous
cancers. Rapid evolution in the field justifies a focused critical review of the clinical literature …

Soft-tissue sarcomas are an uncommon set of malignancies that pose a therapeutic
challenge. Representing a mixture of multiple histologies, approximately 9,000 cases were …

Soft tissue sarcomas are a heterogeneous group of mesenchymal tumors that vary in their
behavior as well as treatment. Certain histologic subtypes predict for response to particular …

Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the current status of the chemotherapeutic treatment of advanced soft tissue sarcomas in …